Why certifications are where AI most often fails pharma
In pharmaceutical manufacturing, certifications and regulatory approvals are among the most important facts a buyer screens for — and among the facts AI models most often get wrong. The difference between WHO-GMP, EU-GMP and US-FDA approval is decisive to a buyer, but when a website lists them loosely, or implies them without stating them, an AI model cannot reliably tell which approvals a company actually holds.
Illustrative before
“Our facility meets the highest international quality and regulatory standards, ensuring global compliance across all our operations.”
A human may read reassurance into this. An AI model reads nothing extractable. It cannot tell whether the company holds US-FDA approval, WHO-GMP certification, EU-GMP, or simply aspires to “high standards.” When a buyer asks specifically for a US-FDA-approved manufacturer, this company cannot be confidently returned — because nothing on the page confirms it.
Illustrative after
“This facility holds US-FDA approval (last inspected [date]), WHO-GMP certification, and EU-GMP certification for oral solid dosage manufacturing. It is approved to supply regulated markets including the US, EU and UK.”
Now each approval is a discrete, named, extractable fact tied to a specific dosage form and a set of markets. When a buyer asks an AI model for a US-FDA-approved oral solid dose manufacturer, the model has exactly the facts it needs to include this company with confidence.
Why this matters commercially
Regulatory approvals are often the first hard filter in a buyer’s shortlist. A manufacturer that genuinely holds an approval but states it vaguely can be filtered out by an AI model that cannot confirm it — losing an opportunity it was fully qualified for. Making approvals legible to AI is one of the highest-value, lowest-effort improvements in AI Discovery.